Avant Technologies Inc. (OTCQB:AVAI)

Las Vegas, NV – August 12, 2025 – Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging technology company developing healthcare solutions, and its Joint Venture partner, Ainnova Tech, Inc. (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that Ainnova is refining its patient recruitment strategy for the Company’s planned clinical trial for its Vision AI platform in the early detection of diabetic retinopathy. Ainnova will work directly with Fortrea, a globally recognized Contract Research Organization (CRO) renowned for its expertise in ophthalmology studies and medical device trials, following the guidance the Company received from its recent meeting with the U.S. Food and Drug Administration (FDA).

 

The planned clinical study, which will be performed in 8-10 clinical sites around the U.S., will prioritize the recruitment of approximately 1,000 multiethnic patients, with a focus on individuals living with diabetes. By targeting community clinics and primary care facilities rather than specialized ophthalmology centers, Ainnova aims to capture real-world data that reflects the diverse population affected by diabetic retinopathy. This strategic approach ensures the study aligns with the practical realities of diabetes care, providing robust and relevant data to support the Company’s FDA 510(k) submission.

 

“We are excited to move forward with an enhanced patient recruitment process,” said Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio. “By focusing on community clinics and targeting a multiethnic group of around 1,000 diabetic patients, we aim to ensure that our study accurately represents the diverse population affected by diabetic retinopathy.

 

“Working with Fortrea, an expert CRO in ophthalmology, allows us to confidently navigate this process with a partner that shares our commitment to quality and efficiency. We are getting closer to initiating a clinical study that will significantly contribute to obtaining FDA 510(k) approval and making our Vision AI platform a crucial tool in early disease detection.”

 

Ainnova’s collaboration with Fortrea underscores its commitment to conducting a rigorous and inclusive clinical study. By leveraging Fortrea’s deep expertise in ophthalmology and medical device trials, Ainnova is well-positioned to deliver high-quality data to support the regulatory approval process to market Vision AI, a platform poised to transform early disease detection for diabetic patients worldwide, in the United States.

 

AAC has the worldwide licensing rights for Ainnova’s technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova’s clinical trial is paramount to marketing the technology portfolio in the United States . Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product.

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada -based healthtech startup with headquarters in San Jose, Costa Rica , and Houston, Texas . Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies Inc.

 

Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com

You can also follow us on social media at:

https://twitter.com/AvantTechAI

https://www.facebook.com/AvantTechAI

https://www.youtube.com/@AvantTechAI

 

In other Biotech/Big Pharma Developments of note:

 

Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives recently announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder.

 

“We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage,” said David Hallett, Chief Scientific Officer of Recursion. “Having full ownership of this important program allows Recursion to accelerate the development of the first potential oral disease-modifying treatment to HPP patients, who currently face significant challenges with limited access to existing therapies. While this is a preclinical asset that will require further study, we look forward to leveraging the full power of the Recursion OS to gain even deeper insights and accelerate delivery of the potential treatment.”

 

BioXcel Therapeutics, Inc. (NASDAQ: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, reported its financial results for the second quarter of 2025 and announced that its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia was complete. Topline results from the study are expected in August.

 

“We are incredibly excited about the upcoming top-line data readout for our SERENITY At-Home Phase 3 trial – our primary market research and preliminary results regarding the frequency of agitation episodes during the trial suggest a target addressable market meaningfully larger than our original estimate of 23 million agitation episodes in the at-home setting annually,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “This expanded opportunity estimate presents a significant prospect to help many bipolar disorder and schizophrenia patients, fulfilling our core mission.”

 

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc., President and CEO: Naoki Okamura, “Astellas”) announced positive topline results from the Phase 3 EV-303 clinical trial (also known as KEYNOTE-905). The EV-303 study is evaluating PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor, as neoadjuvant and adjuvant treatment (before and after surgery) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy.

 

At the first interim efficacy analysis, the trial demonstrated a clinically meaningful and statistically significant improvement in event-free survival (EFS), the study’s primary endpoint, and overall survival (OS), a key secondary endpoint, with neoadjuvant and adjuvant PADCEV plus KEYTRUDA versus surgery alone. An additional secondary endpoint of pathologic complete response (pCR) rate was also met.

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.  Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov ). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

SOURCE Avant Technologies Inc.

 

At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies. #tickertagpressreleases #pressreleases

 

Follow us on Facebook to receive the latest news updates: https://www.facebook.com/financialnewsmedia

Follow us on Twitter for real time Market News: https://twitter.com/FNMgroup

Follow us on Linkedin: https://www.linkedin.com/in/financialnewsmedia/

 

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Las Vegas, NV – July 22, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging technology company developing healthcare solutions using both artificial intelligence (AI) and developments in biotechnology, today announced that Vinicio Vargas, Chief Executive Officer (CEO) of Avant’s partner, Ainnova Tech, Inc., (Ainnova), was a featured speaker Friday and Saturday at Roche’s Latin America “Macular Spectacular” Ophthalmology conference in Cartagena, Colombia.

 

The conference highlighted the latest in scientific advances in treatments for the most common eye diseases, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, while also focusing on strengthening collaboration between industry specialists in Latin America.

 

Ainnova’s CEO, Vinicio Vargas, who is also a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio, discussed the status of AI and its uses in the industry to improve patient outcomes. Vargas and a host of renowned speakers that included Dr. Laura Velásquez, Dr. Roberto Gallego, Hugo Ocampo, and other ophthalmologists and experts presented the latest tools to transform visual health in the region, reflected on unmet needs, and explained how innovation can help build stronger, accessible, and patient-centered health systems.

 

In Q4 2024, Ainnova entered a strategic alliance with global biotech, Roche, and leading pre-paid health plan provider, Salud 360, to start a pilot program to combat diabetic retinopathy using Ainnova’s AI-powered, cutting-edge technology, Vision AI. The alliance aims at improving access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy.

 

If the program is successful, Avant and Ainnova hope to implement a similar program in the United States, Canada, and Europe through AAC. AAC has the worldwide licensing rights for Ainnova’s technology portfolio, which includes Ainnova’s Vision AI platform.

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com

 

You can also follow us on social media at:
Tweets by AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

Source: Avant Technologies, Inc.

Las Vegas, NV – July 15, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the completion of its milestone meeting with the U.S. Food and Drug Administration (FDA). The pre-submission meeting allowed Ainnova and its Contract Research Organization (CRO), Fortrea, to present and discuss Ainnova’s planned clinical trial for its Vision AI platform in the early detection of diabetic retinopathy and receive critical feedback from the FDA.

 

Ainnova’s clinical trial will be conducted exclusively in the United States and focus solely on diabetic retinopathy. The FDA has now provided the Company with valuable guidance on its clinical protocol, the number and type of clinics Ainnova will need to conduct a successful clinical trial, the number of retinologists required to examine the images generated by Ainnova’s Vision AI, etc.

 

With the FDA’s recommendations, the Company can now actively plan for the total cost of conducting this planned clinical trial through to completion. Data from Ainnova’s trial will support the Company’s FDA 510(k) submission to obtain clearance from the FDA to market the Vision AI technology in the United States.

 

Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio, said, “We’re truly excited about this next phase. We’re getting ready to begin data collection across primary care clinics in the U.S. with a study that is simple, yet rigorous—comparing our AI-based retinal screening to the readings of three retinologists.

 

“This milestone not only brings us closer to validating our platform in the world’s largest healthcare market, but it also paves the way for the upcoming approval of our new automated retinal camera, which we believe will be a game changer—making diabetic retinal screenings faster, more accessible, and available from virtually any point of care.”

 

AAC has the worldwide licensing rights for Ainnova’s technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova’s clinical trial is paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product.

 

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
Tweets by AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
SOURCE: Avant Technologies, Inc.
info@avanttechnologies.com

Las Vegas, NV – June 17, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that screenings for diabetic retinopathy begin this week in collaboration with Grupo Dökka and its leading pharmacy subsidiaries, Fischel Pharmacies and La Bomba Pharmacies located in Central America.

 

Both Fischel and La Bomba Pharmacies have asked their diabetic customers to schedule a free screening as part of a collaborative program where Ainnova will use its cutting-edge AI platform, Vision AI, to help identify changes in the retina using a quick and non-invasive scan of the patient’s retina.

 

Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp., a joint venture company created by both Avant and Ainnova, said of the benefits for the collaboration, “As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment—connecting every step of the journey. We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive: the well-being of the diabetic patient. Projects like this allow us to validate the model across diverse populations and sectors as part of our strategy to reach the market in a smarter, more efficient way—where the biggest winners are the patients.”

 

Diabetic retinopathy is one of the main causes of vision loss in people with diabetes. Although, in its early stages, it may not present symptoms, it can be detected with a simple and quick screening. The screenings are important for:

 

Prevention: Screenings will detect changes in the retina before they affect vision.
Speed: Each screening takes only a few minutes.
Peace of Mind: Patients will receive the results of the screening in a secure and timely manner.

 

Grupo Dökka, which operates in Costa Rica, Nicaragua, and Panama with expansion expected into other Central American countries, has created numerous innovative platforms, including storage and distribution, pharmacies, and marketing and sales, that provide access to comprehensive health and well-being solutions for all people.

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com

You can also follow us on social media at:
Tweets by AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

Source:  Avant Technologies, Inc.

Las Vegas, NV – June 4, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the Company is in the final stages of prototyping its proprietary automated retinal camera. Ainnova’s new device will offer users a low cost, easier to use camera that captures images automatically and then uploads those images to the Company’s Vision AI software platform, which then produces a “risk report” in mere seconds.

 

Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said, “The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market.

 

“Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists. Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach.”

 

Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration, and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova has integrated into the software like the detection of cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD).

 

Currently, Ainnova’s Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera.

 

Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova’s technology portfolio. AAC owns the global licensing rights to develop, maintain, and market Ainnova’s technology portfolio.

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
Tweets by AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

Source: Avant Technologies, Inc.

Las Vegas, NV – May 12, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies and their advisors have entered into negotiations for an acquisition to better compete in the rapidly changing global AI-driven healthcare industry.

 

Six months ago, the two companies formed Ai-nova Acquisition Corp. (AAC) to advance and commercialize Ainnova’s technology portfolio, including its Vision AI platform and its versatile retinal cameras. During that time, the two companies completed further due diligence and focused on an opportunity to work together as one company. The Board of Directors and management team of Avant remain fully committed to executing the Company’s strategic plan, which is focused on enhancing long-term value. Leadership at Avant expects the negotiations to move forward with an acquisition of Ainnova.

 

Both Avant and Ainnova agree that the time is now to solidify the relationship and move forward as one entity prior to the Company’s pre-submission meeting with the U.S. Food and Drug Administration in July for the planned clinical trial of its Vision AI platform in the early detection of diabetic retinopathy.

 

Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp., said of the negotiations, “We believe bringing the two companies together will offer tremendous value for shareholders, it will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally.

 

We feel the joint venture has been a success and both companies have worked well together toward a common goal, so we believe that we can be even more successful and use our resources more effectively as one company to further AI in healthcare.”

 

Currently, AAC has the worldwide licensing rights for Ainnova’s technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so both companies expect that an acquisition will unlock growth opportunities and drive sustained performance as both entities plan to interact with the FDA in July for an upcoming clinical trial working even more closely together under one banner.

 

Vargas continued, “The success of our interactions with the FDA are crucial to our success in the clinic and eventually the success of marketing our technology portfolio in the United States and around the world. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures that we can do so with speed, credibility, and a validated product.”

 

Avant will inform its shareholders of any updates at an appropriate time.

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:

 

Tweets by AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

Source:  Avant Technologies, Inc.

Las Vegas, NV – April 29, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that The Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) has received the company’s submission package requesting a pre-submission meeting with the FDA for its VisionAI platform technology and is now under review.

 

Ainnova is requesting a pre-submission meeting with the FDA’s review team to discuss any questions and/or concerns about its proposed formal submission, including seeking advice to finalize the protocol and obtain agency guidance for a clinical trial of its VisionAI platform in the early detection of diabetic retinopathy. A pre-submission meeting allows companies to clarify regulatory requirements, get feedback on their plans, and potentially avoid delays or issues during the formal review process.

 

The clinical studies will aim to support an FDA 510(k) submission to obtain clearance from the regulatory agency to market its technology in the U.S.

 

Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio, including its VisionAI platform and its versatile retinal cameras, has worldwide licensing rights for this portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova’s interactions with the FDA are paramount to marketing the technology portfolio in the United States.

 

Vinicio Vargas, Chief Executive Officer at Ainnova and a member of AAC’s Board of Directors, said, “This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where VisionAI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market. Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product.”

 

For medical device applicants like Ainnova, the FDA’s pre-submission program is useful to determine a clear regulatory pathway for the successful launch of the device, including the number of patients and the number of clinics that will be needed to generate the necessary clinical data for the FDA to make an informed decision on Ainnova’s VisionAI platform. For Avant, the pre-submission meeting will help define a precise budget for the strategic partnership’s entire FDA process.

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at

 

Main Home

You can also follow us on social media at:
Tweets by AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

SOURCE:  Avant Technologies, Inc.

Las Vegas, NV – April 16, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that following Ainnova’s sponsorship and its CEO’s key role at the 2025 Healthcare Innovation Summit in Mexico City, both Avant and Ainnova, through their joint venture, Ai-nova Acquisition Corp. (AAC), are building on Ainnova’s strong presence in Mexico by expanding its footprint across Latin America.

 

Ainnova has initiated its first commercial pilots in both Chile and the Dominican Republic to work directly with prestigious hospitals that cover the full spectrum of care—from primary to highly specialized services. These pilot programs aim to demonstrate, (i) cost reduction in preventive diagnostics; (ii) increased efficiency in medical resource allocation and patient flow; (iii) enhanced institutional reputation driven by technological innovation; and (iv) improved profitability for participating healthcare centers through optimized patient referrals.

 

The pilot programs leverage Ainnova’s proprietary Vision AI platform to identify health risks in real time, which enable seamless referrals for specialty care or further diagnostic tests when a positive risk is detected. The broader vision for the joint venture involves deploying an automated, low-cost retinal imaging device integrated with its AI-driven platform to deliver comprehensive preventive risk screening. From just two retinal images, blood pressure and some lab test information, the system will assess risks for: cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD).

 

The message that Ainnova’s CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years.

 

Avant has partnered with Ainnova to form AAC so the two companies can advance and commercialize Ainnova’s technology portfolio worldwide. AAC has the global licensing rights for the portfolio, including its Vision AI platform and its versatile retinal cameras.

 

Avant and Ainnova have identified Brazil and the United States as key strategic markets. Ainnova is currently addressing regulatory pathways in Brazil with the support of its MDSAP certification to meet ANVISA requirements, paving the way for rapid market entry.

 

At the same time, Ainnova is advancing its regulatory roadmap for the U. S. The objective is to begin clinical trials in the coming months to obtain FDA approval and commercialize its technology in the U.S.—initially targeting markets where reimbursement codes for diabetic retinopathy are already approved.

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com

 

You can also follow us on social media at:

 

Tweets by AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

Source: Avant Technologies, Inc.

Las Vegas, NV – March 25, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the Company has started designing its clinical trial protocol ahead of a pre-submission meeting with the U.S. Food and Drug Administration (FDA). The pre-submission meeting is to request guidance on the clinical testing needed for its Vision AI platform in the early detection of diabetic retinopathy, and Ainnova’s clinical trial will culminate in the submission of an FDA 510(k) to obtain clearance from the regulatory agency to market its technology.

 

Ainnova has hired an ophthalmologist, who is assisting in drafting the requirements for the clinical trial protocol that the Company’s Contract Research Organization (CRO), Fortrea, has requested. Upon completion of the protocol, Ainnova will work with its CRO to prepare and send all the documentation to the FDA for its upcoming pre-submission meeting. A clinical trial protocol is a detailed, written plan that outlines the objectives, design, methodology, and organization of a clinical research project, ensuring the safety of participants and the integrity of data collected. The Company expects its pre-submission meeting with the FDA to occur in mid-May 2025.

 

Ai-nova Acquisition Corp. (AAC), the Company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio, including its Vision AI platform and its versatile retinal cameras, has the global licensing rights for this portfolio, so the success of Ainnova’s interactions with the FDA are paramount to marketing the technology portfolio in the United States.

 

For medical device applicants like Ainnova, the FDA’s pre-submission program is useful to determine a clear regulatory pathway for the successful launch of the device, including the number of patients and the number of clinics needed to generate the necessary clinical data for the FDA to make an informed decision on Ainnova’s Vision AI platform. For Avant, the pre-submission meeting will help define a precise budget for the strategic partnership’s entire FDA process.

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com

You can also follow us on social media at:

Tweets by AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

Source: Avant Technologies, Inc.

Las Vegas, NV – March 10, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that Apollo Hospitals (Apollo) and Ainnova have officially established a strategic collaboration that marks a significant step forward in the integration of artificial intelligence into disease detection and prediction.

 

As part of this alliance, Ainnova has secured an exclusive license for several advanced AI algorithms, which have been rigorously validated with over 2.3 million data points and now form an integral part of Ainnova’s Vision AI platform. These cutting-edge solutions enable the early and precise detection of conditions, such as cardiovascular disease (CVD), chronic kidney disease (CKD), liver fibrosis, type 2 Diabetes, and lung abnormalities in CT scans and X-rays, including lung cancer.

 

Last month, Avant and Ainnova signed a global development and licensing deal for Ai-Nova Acquisition Corp. (AAC), the joint venture formed by both companies. Given AAC’s territory now includes a global license to develop and market Ainnova’s technology portfolio, this partnership with Apollo strengthens the joint venture’s efforts to advance AI in Healthcare using Ainnova’s Vision AI platform and its proprietary versatile retinal camera technology.

 

This week, most of these AI-driven diagnostics will be available exclusively on the Vision AI platform across the Americas, where the first commercial pilot programs are set to launch in the coming weeks.

 

Notably, Brazil is already included in the expansion roadmap, as the partnership has successfully met the regulatory requirements set by ANVISA (Brazilian Health Regulatory Agency). This milestone paves the way for commercialization in a country with over 200-million people.

 

The integration of these AI-powered solutions aligns with efforts to enhance chronic disease management by adding substantial value to patient care. By providing a comprehensive preventive health assessment, these tools aim to facilitate early referrals from primary care providers or community health services, such as pharmacies, to specialized medical professionals.

 

Apollo Hospitals is one of the largest and most renowned private healthcare networks in Asia, playing a leading role in transforming healthcare in India and across Southeast Asia. With a robust presence that includes hospitals, clinics, pharmacies, and diagnostic centers in the region and beyond, Apollo remains at the forefront of medical innovation.

 

With this alliance, Apollo reaffirms its commitment to advancing global healthcare by leveraging AI-powered solutions. Partnering with Ainnova in the Americas underscores its dedication to driving innovation, improving patient outcomes, and expanding access to state-of-the-art medical technologies. Together, the two organizations will continue to develop and deploy AI-driven healthcare solutions with additional innovations set to be introduced in the near future.

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Apollo Hospitals

 

Apollo revolutionized healthcare when Dr. Prathap Reddy opened the first hospital in Chennai in 1983. Today, Apollo is India’s largest integrated healthcare platform with over 10,000 beds across 73 hospitals, over 6000 pharmacies and over 200 clinics and diagnostic centers, as well as 150 telemedicine centers. It is the world’s leading cardiac center with over 200,000 surgeries and the world’s largest private cancer care provider. Apollo continues to invest in research to bring the most cutting-edge technologies, equipment, and treatment protocols to ensure patients have the best available care in the world. Apollo’s 100,000 family members are dedicated to bringing you the best care and leaving the world better than we found it.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
Tweets by AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

Source:  Avant Technologies, Inc.

Las Vegas, NV – February 11, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”) and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the selection of Fortrea, a global provider of clinical development solutions to the life sciences industry, as the contract research organization (CRO) to conduct Ainnova’s upcoming clinical studies to seek approval from the U.S. Food and Drug Administration (FDA) for Ainnova’s Vision AI platform.

 

Fortrea will assist Ainnova in requesting a pre-submission meeting with the FDA for guidance on the clinical testing needed for its Vision AI platform in the early detection of diabetic retinopathy. After a pre-submission meeting, Fortrea will then work with Ainnova on its FDA submission and a subsequent clinical study before concluding with an FDA 510(k) submission to obtain clearance from the FDA to market its Vision AI platform.

 

The upcoming clinical studies are significant to Avant and its shareholders because of the partnership formed by Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio, including its Vision AI platform and its versatile retinal cameras. The joint venture formed by the two companies, Ai-nova Acquisition Corp. (AAC), has the licensing rights for this portfolio in the U.S., Canada, and Europe, so the success of Ainnova’s clinical studies with the FDA will be vital to marketing the technology portfolio in the United States.

 

Ainnova’s Chief Executive Officer, Vinicio Vargas, said of the selection, “We worked diligently to identify and select the right CRO to help us both engage the FDA and then conduct our clinical studies. Fortrea is an established and highly regarded full-service CRO with expertise in more than 20 therapeutic areas, and a CRO with an extensive portfolio of successfully completed clinical trials, including those involving both emerging and large biopharmaceutical, medical device, and diagnostic companies.”

 

With Fortrea’s guidance, Ainnova expects to submit its pre-submission application in the coming weeks and expects to meet with the FDA for its pre-submission meeting in late March/early April 2025. Additionally, Ainnova will also interact with the FDA to devise a plan to obtain clearance for four algorithms it recently acquired the exclusive licensing rights to, which include early detection for cardiovascular risk, prediabetes and Type 2 diabetes, fatty liver disease, and chronic kidney disease.

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
Tweets by AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

Source:  Avant Technologies, Inc.

Las Vegas, NV – January 16, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that Ainnova has started the process of implementing the 4 advanced AI-driven algorithms the company acquired last month into its state-of-the-art Vision AI platform.

 

During the implementation, Ainnova will configure the APIs within its platform, update the functionalities, and then test the new groundbreaking algorithms on a demo population group. The demo group will offer valuable feedback ahead of the Vision AI platform being introduced in several commercial pilot programs in Latin America with strategic partners in primary healthcare services across key markets in the region, including with two major pharmaceutical companies in Costa Rica and in Mexico, and in partnership with several pharmacy chains equipped with labs on site throughout Mexico.

 

The 4 algorithms include early detection for cardiovascular risk, prediabetes and type 2 diabetes, fatty liver disease, and chronic kidney disease. Combined with Ainnova’s existing retinal disease detection tools, these new algorithms will be used with Ainnova’s Vision AI to detect the early markers of these diseases quickly and accurately by applying AI.

 

The 4 algorithms include early detection for cardiovascular risk, prediabetes and type 2 diabetes, fatty liver disease, and chronic kidney disease. Combined with Ainnova’s existing retinal disease detection tools, these new algorithms will be used with Ainnova’s Vision AI to detect the early markers of these diseases quickly and accurately by applying AI.

 

Ainnova’s Chief Executive Officer, Vinicio Vargas, said, “Patients with chronic conditions face a variety of complications. The ability to screen these individuals in basic health services or during routine primary care check-ups, using fast, non-invasive tests powered by AI, is transformative. Such technology enables highly accurate and timely detection of potential risks or issues, which ensures that patients are referred efficiently to the appropriate specialist. This approach has the potential to significantly enhance patient outcomes and streamline healthcare processes.”

 

The acquisition of an exclusive license to use 4 advanced algorithms in the Americas from one of Asia’s most respected and largest healthcare institutions, offers Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, a robust platform for primary care providers to streamline early risk screening and improving patient care throughout the Americas. AAC expects to build on Ainnova’s regional expansion by securing clearance from the U.S. Food and Drug Administration in 2025 to then introduce these solutions in the U.S. market.

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
Tweets by AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

Source:  Avant Technologies, Inc.

Las Vegas, NV – December 17, 2024 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its partner, Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced Ainnova’s acquisition of an exclusive license for 4 groundbreaking, AI-driven algorithms from one of Asia’s most respected and largest healthcare institutions.  These solutions, validated across diverse geographies, ethnicities, and socio-economic populations with data from over 2-million patients, will join Ainnova’s existing diabetic retinopathy and retinal disease detection solutions.

 

The 4 algorithms include early detection for cardiovascular risk, prediabetes and type 2 diabetes, fatty liver disease, and chronic kidney disease.  Combined with Ainnova’s existing retinal disease detection tools, these new algorithms will be used with Ainnova’s powerful cutting-edge AI platform, VisionAI, to detect the early markers of these diseases quickly and accurately by applying AI.

 

The acquisition of an exclusive license to use 4 advanced algorithms in the Americas offers Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, a robust platform for primary care providers to streamline early risk screening and improving patient care in the United States.

 

Ainnova will introduce these cutting-edge solutions in Latin America with strategic partners in primary healthcare services across key markets like Mexico and Brazil.  AAC expects to build on Ainnova’s regional expansion by securing clearance from the U.S. Food and Drug Administration in 2025 to then introduce these solutions in the U.S. market.

 

While explaining that these efforts aim to transform the current approach to preventive care by providing accessible, efficient, and impactful health screening solutions, Ainnova’s Chief Executive Officer, Vinicio Vargas, said, “This license represents a pivotal moment for Ainnova and for its partnership with Avant as it allows us to bring world class, validated solutions to the Americas.  This effort not only complements our current solutions, but it also aligns with our ongoing R&D initiatives to continue incorporating new diseases that can be detected quickly and affordably, pushing the boundaries of preventive care, and making healthcare more inclusive and accessible to all.”

 

The licensed algorithms enhance the company’s capabilities to empower healthcare providers with comprehensive, fast, and accessible tools for early disease detection.  Using simple patient datapoints—such as demographics, lifestyle attributes, and routine measures, like blood pressure—these algorithms enable rapid risk screening, facilitating timely specialist referrals and improving health outcomes.

 

Key Features and Benefits of the New Algorithms:

 

1. Cardiovascular Risk Assessment:

• Accurately predicts coronary artery disease risk with over 90% precision.
• Offers personalized recommendations through a Clinical Decision Support System (CDSS), enabling targeted preventive measures.

 

2. Prediabetes and Type 2 Diabetes Prediction:

• Predicts the three-year risk of diabetes with an AUC of 0.861, using demographic and lifestyle data.
• Provides tailored care plans and actionable insights to prevent disease progression.

 

3. Liver Fibrosis Screening:

• Identifies patients at risk of advanced liver fibrosis with accuracy exceeding 88%.
• Supports timely referral and management of non-alcoholic fatty liver disease.

 

4. Chronic Kidney Disease (CKD) Monitoring:

• Predicts CKD progression and supports preventive interventions to slow disease advancement.
• Guides care through integrated analysis of clinical and laboratory data.

 

Vargas added, “This robust AI platform marks a significant step toward global adoption, ensuring that advanced AI tools are accessible to healthcare systems everywhere.”

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare.  With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com

 

You can also follow us on social media at:

 

https://twitter.com/AvantTechAI

https://www.linkedin.com/company/avant-technologies-ai

https://www.facebook.com/AvantTechAI

https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.”  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.  Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:

Avant Technologies, Inc.

info@avanttechnologies.com

 

Source:  Avant Technologies, Inc.

Las Vegas, NV – December 4, 2024 – Avant Technologies, Inc.’s (OTCQB: AVAI) (“Avant” or the “Company”), partner, Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the company has entered into a strategic alliance with global biotech, Roche, and leading pre-paid health plan provider, Salud 360, to begin a pilot program to combat diabetic retinopathy using Ainnova’s cutting-edge technology.

 

The pilot program will initially be implemented in Costa Rica where diabetes affects about 10.4% of the adult population. [1] If successful, Avant and Ainnova hope to implement a similar program in the United States, Canada, and Europe through Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova.

 

According to data from the Costa Rican Institute for Research and Teaching in Nutrition and Health (Inciensa), uncontrolled diabetes is the leading cause of preventable blindness in the country’s adult population. To make matters worse, between 20% and 40% of diabetic patients develop diabetic retinopathy, a silent but devastating condition if not detected and treated in time.

 

According to the World Health Organization, 80% of cases of blindness due to diabetes are preventable with early and effective interventions.[2] Therefore, early detection is crucial and technological innovation can help make a huge difference.

 

Roche, Ainnova, and Salud 360 signed a strategic alliance to improve access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy using Ainnova’s advanced technology and a patient-centered approach.

 

The pilot program will use non-mydriatic fundus cameras and artificial intelligence—developed by Ainnova Tech—to automatically analyze retinal images and identify microscopic changes in the retina. Such changes would be an early indicator of diabetic retinopathy without the need for invasive tests.

 

“At Roche, we are committed to timely diagnosis of diseases to improve clinical outcomes and thus contribute to the sustainability of the healthcare system. By leveraging technology, we seek to improve lives, optimize diagnoses, and ensure that every patient has access to timely and effective treatment. With this model, we not only seek to address the problem of diabetic retinopathy, but also to establish a replicable path for other diseases that require innovative solutions,” said, Alvaro Soto, General Manager of Roche Central America, Caribbean, and Venezuela.

 

By implementing the pilot program in Costa Rica, this strategic alliance can take advantage of the country’s robust healthcare system and its focus on technological innovation. Patients who are members of Salud 360 will be the first to benefit from screenings at affiliated clinics. Those at risk will be referred immediately to ophthalmology specialists, guaranteeing comprehensive and timely care.

 

The results of this pilot program will be the basis for developing the model beyond our borders to benefit communities facing similar challenges in accessing medical care.

 

Vinicio Vargas, Chief Executive Officer of Ainnova Tech and member of AAC’s Board of Directors, emphasized, “We are proud to be able to put our technology at the service of a project that has the potential to prove itself as a massive impact model in early detection, and which we believe is replicable globally. Today, we are starting with diabetic retinopathy, but the vision is that we can eventually multiply this same effort for other critical diseases that require innovative solutions.”

 

[1] https://www.ministeriodesalud.go.cr/index.php/comunicados-de-prensa/3-newsflash/360-ministerio-de-salud-somete-a-consulta-reglamento-ley-control-de-tabaco
[2] https://www.who.int/es/news-room/fact-sheets/detail/blindness-and-visual-impairment

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

Source: Avant Technologies, Inc.

Las Vegas, NV – November 20, 2024 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its partner Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies will advance Ainnova’s proprietary low-cost retinal camera, which will be used for fundus photography, and seamlessly packaged together with Ainnova’s Vision AI software platform for commercialization. By combining the two technologies, Ainnova’s versatile camera will provide precise retinal scans to its AI software leading to even more accurate data.

 

Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova will integrate into the software like the detection of kidney disease, liver fat, cardiovascular risk, and pre-iabetes.

 

Currently, Ainnova’s Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera that captures retinal images automatically and then uploads those images to the Vision AI software platform, which then produces a “risk report” in mere seconds. Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova’s technology portfolio. AAC owns the licensing rights to develop, maintain, and market Ainnova’s technology portfolio in both North America (United States and Canada) and throughout Europe.

 

Vinicio Vargas, Chief Executive Officer of Ainnova and member of AAC’s Board of Directors, said, “The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera should allow us to not only enter the market, but to capture a large share of the market. To that end, I will be meeting with a leading U.S. provider of digital healthcare solutions to discuss a potential distribution agreement, investment, and regulatory support.”

 

AAC will market the two technologies as a Software as a Service (SaaS) + retinal camera package with the hope of making retinal scans a part of routine healthcare. The business model is a pay-per-use platform, per patient, monthly, aimed at primary care clinics, insurance companies, opticians, pharmacies, occupational health companies that provide the service to employees of many companies, and pharmaceutical companies that sell the treatments or therapies.

 

Vinicio Vargas added, “Our vision is that the retina will be a new standard in primary care, as basic as taking a patient’s blood pressure, and together with other datapoints, such as demographic data or laboratory results, to generate a complete report of preventive medicine.

 

“The goal is to provide patients with a risk screening so that they can be referred to the appropriate specialist. Our proprietary retinal camera, combined with our VisionAI software technology will offer a real accessible opportunity for early detection—and this is how we are going to impact the world.”

 

Ainnova currently has commercial agreements with pharmaceutical companies, clinics, insurance companies, and medical service providers, and these relationships should offer AAC guidance into marketing the SaaS + retinal camera package in the North American and European markets.

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

You can also follow us on social media at:

Tweets by AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Source: Avant Technologies, Inc.
info@avanttechnologies.com

Las Vegas, NV – November 12, 2024 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and Ainnova Tech, Inc., (Ainnova) a leading healthcare technology (healthtech) company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies have entered into a joint venture and licensing agreement with the formation of Ai-nova Acquisition Corp (AAC).  The partnership was formed to advance and commercialize Ainnova’s technology portfolio, including its “VisionAI” platform and its “Versatile Retinal Cameras.”

 

Ainnova will contribute to AAC its proprietary technology portfolio, including VisionAI and its retinal camera technology, and the licensing rights for AAC to develop, maintain, and commercialize the technology portfolio in both North America (United States and Canada) and Europe, while Avant will be responsible for the capital requirements to operate AAC.

 

VisionAI is a cutting-edge, AI-driven platform that can detect diabetic retinopathy and other retinal diseases, as well as diseases unrelated to the retina like cardiovascular disease and potentially even Alzheimer’s with high accuracy and speed using retinal scans.  Meanwhile, Ainnova’s next-generation versatile retinal cameras are seamlessly integrated with VisionAI for precise retinal scans.  Along with the VisionAI software, Ainnova’s retinal cameras, offer AAC SaaS + retinal camera commercialization opportunities with opticians and eye care centers in two extremely profitable markets, North America and Europe.

 

Ainnova and Avant’s partnership seeks to make retinal scanning a new standard in primary care and basic health services by diagnosing a host of diseases early through a simple visual test that AAC can offer as a scalable and accessible solution.

 

Vinicio Vargas, Chief Executive Officer of Ainnova, commenting on the partnership said, “This joint venture aligns perfectly with our long-term goals, and as we work together to push the boundaries of what’s possible in the healthtech sector, we look forward to setting new standards and bringing transformative solutions to patients around the world in an accessible way.”

 

With over 500 million people living with diabetes globally, VisionAI is designed to detect the early markers of diseases like diabetic retinopathy, which is the leading cause of blindness among working age adults. Over 30% of those living with diabetes will develop diabetic retinopathy, a disease that can be prevented with an accurate diagnosis.

 

Unfortunately, there aren’t enough ophthalmologists globally.  And 95% of cases of blindness due to diabetic retinopathy can easily be prevented with an early and accurate diagnosis.  Using advanced algorithms to analyze retinal images with precision, reliability, and speed, VisionAI can bridge the gap between too few ophthalmologists and tens of thousands of people who need to get tested.

 

According to Ainnova, the diagnostic error rate in diabetic retinopathy is about 49% and this is where VisionAI offers a positive impact for patients.  VisionAI is a powerful tool to support the physician and give their patients accurate information that can improve their lives.

 

This partnership makes sense for Avant and its shareholders given the AI in healthcare market is projected to grow from $6.9 billion just 3 years ago to $67.4 billion by 2027, at a CAGR of 46.2% during the forecast period.  Ainnova currently has commercial agreements with Pharma companies, clinics, insurance companies, and medical service companies.  These relationships should offer AAC guidance into the North American and European markets.

 

About Ainnova Tech, Inc.

 

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare.  With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com

 

You can also follow us on social media at:

 

https://twitter.com/AvantTechAI

https://www.linkedin.com/company/avant-technologies-ai

https://www.facebook.com/AvantTechAI

https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.”  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.  Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:

Avant Technologies, Inc.

info@avanttechnologies.com

 

Source:  Avant Technologies, Inc.

Palm Beach, FL – August 14, 2024 – FN Media Group News Commentary – The technological shift driven by the rise of artificial intelligence (AI) is giving patients in the USA cautious optimism towards the potential of generative AI in healthcare. In order to safely bring AI into the healthcare space, state governments across the USA are working on how to regulate its implementation. The potential to enhance accuracy and speed in diagnostics, analyzing eye scans and predicting complications, and even designing new drugs, the potential for AI in healthcare is too big to ignore. Reaching the goal of safely bringing AI into the medical space still requires lots of research and development, with several tech innovators recently updating the market with their latest developments, including: Avant Technologies Inc. (OTCQB: AVAI), Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), Exscientia plc (NASDAQ: EXAI), Twist Bioscience Corporation (NASDAQ: TWST) and IQVIA Holdings Inc. (NYSE: IQV).

 

The article continued: Driven by advancements in machine learning techniques, analysts at MarketsandMarkets Research are projecting explosive growth (48.1% CAGR) in the AI in Healthcare Market, estimating it to reach US$148.4 billion by 2029. Also recently, Silicon Valley Bank published a report, claiming that 1 in 4 dollars invested in healthcare are going towards companies leveraging AI.

 

Avant Technologies, Inc. (OTCQB: AVAI) Unveils AI-Powered Healthcare Infrastructure to Deliver Intelligent Healthcare Solutions – Avant Technologies, Inc. (“Avant” or the “Company”), an emerging technology company developing solutions in artificial intelligence (AI) infrastructure while exploring additional technologies in the biotechnology and healthcare sectors, today announced a significant initiative to improve patient care by creating an advanced AI-powered healthcare infrastructure. This new platform will utilize machine learning and advanced computing to empower healthcare providers and patients, which will enhance care delivery and monitoring. Healthcare-focused applications, such as “intelligent agents,” will directly benefit from this platform, which includes built-in features specifically designed for healthcare applications for professionals and patients.

 

Avant’s vision for the future of healthcare revolves around integrating with existing systems and providing a suite of built-in infrastructure and intelligent features. These features include first- line advising agents that offer personalized guidance to patients, advanced analytics to uncover hidden patterns and optimize treatment plans, and tailored treatment protocols based on individual patient data. The platform will also include a predictive health analysis feature for early intervention and medication management tools to ensure optimal adherence and effectiveness.

 

One of the infrastructure’s key focuses is a highly secure connection to clinic and hospital patient databases. This ensures privacy and compliance while enabling remote telemedicine features. It also expands access to quality healthcare, especially in underserved areas.

 

“Our mission is to utilize the latest advancements in AI, including the massive potential of future quantum computing, to create a healthcare ecosystem where healthcare applications can naturally incorporate smart features for patient care, ensuring that every patient receives the best possible care,” said Kenneth L. Waggoner, Chief Executive Officer at Avant Technologies. “We believe that evidence-based medicine and intelligent resource allocation will pave the way for a healthier future for all.”

 

Avant’s ambition extends beyond improving patient outcomes. By optimizing healthcare spending through intelligent data-driven insights, the company aims to make quality healthcare more accessible and affordable for everyone. This initiative reinforces Avant’s commitment to utilizing cutting-edge technology to create a more efficient, effective, and equitable healthcare system for the future.  CONTINUED… Read this and more news for Avant Technologies at:   https://www.financialnewsmedia.com/news-avai/

 

In other industry developments and happenings in the market recently include:

 

TechBio companies Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) and Exscientia plc (NASDAQ: EXAI), recently announced a definitive agreement to create a global technology-enabled drug discovery leader with end-to-end capabilities.

 

The collaboration brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform. Together they have a highly complementary pipeline with approximately 10 clinical readouts expected over the next 18 months. The duo expects their complementary operations to yield annual synergies of approximately $100 million.

 

The combination will prioritize generative AI design, including both 2D and 3D modeling, to drive advancements in structure-based drug design, hotspot analysis, and quantum mechanics. It will support a comprehensive, technology-enabled platform that spans patient-centric target discovery, molecular dynamics modeling, automated chemical synthesis, predictive ADMET, biomarker selection, clinical development, and more. This full-stack platform will also encode and automate design-make-test-learn cycles with active learning.

 

“We believe the proposed combination is deeply complementary and aligned with our missions to industrialize drug discovery to deliver high quality medicines and lower prices for consumers,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion as well as the planned CEO of the combined entity. “Exscientia’s precision chemistry tools and capabilities, including its newly commissioned automated small molecule synthesis platform, will augment our tech-enabled biology and chemistry exploration, hit discovery and translational capabilities.”

 

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, recently announced the expansion of its DNA synthesis offering with the launch of Gene Fragments with increased lengths ranging from 1.8kb to 5.0kb.

 

Twist’s low error rate of 1:7,500 base pairs facilitate the production of longer gene fragments, seamlessly integrating into workflows and enabling researchers to select fewer colonies for screening or directly use the fragments in in vitro transcription to produce RNA. The extended length of these Gene Fragments allows researchers to further customize and incorporate additional elements. Turnaround time for all Gene Fragments, regardless of length, begins at just two business days.

 

“Leveraging our Express Genes workflow, industry-leading error rate and rapid turnaround times, we continue to push the boundaries of what is possible in DNA synthesis to expand our portfolio of products that enable our customers to quickly and efficiently advance their research,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “With the versatility, speed, high quality, scalability, competitive pricing, and now increased length of Twist Gene Fragments, we can further penetrate the Maker’s Market and meet the needs of customers who previously had to stitch together shorter fragments, as well as enable customers working in RNA therapeutic screening applications.”

 

IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry recently reported its Q2 2024 results, which included R&D Solutions quarterly bookings of $2.7 billion, representing a book-to-bill ratio of 1.27x, and a R&D Solutions contracted backlog of $30.6 billion, up 7.7% reported and 8.1 percent at constant currency year-over-year.

 

These positive results followed upon IQVIA’s recent recognition by independent research firm, Everest Group, as a Leader in its Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024 survey, which measures both market impact and delivery effectiveness. As with all IQVIA AI-powered solutions, the AI capabilities in IQVIA’s medical affairs and regulatory solutions are grounded in IQVIA Healthcare-grade AI™ – AI engineered to meet the level of precision, speed and trust required for life sciences and healthcare.

 

“IQVIA stands out as a prominent service provider distinguished by its wide scope of services and extensive domain expertise, which is further augmented through its collaborations with multiple health authorities,” says Lloyd Fernandes, practice director, Everest Group. “Furthermore, IQVIA is well-poised to cater to enterprises’ digitization needs via its suite of technology solutions, including IQVIA RIM Smart, productivity tools for electronic submissions, and IQVIA labeling solutions, enabling enhanced process efficiencies.”

 

About FN Media Group:

At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies. #tickertagpressreleases #pressreleases

 

Follow us on Facebook to receive the latest news updates: https://www.facebook.com/financialnewsmedia

Follow us on Twitter for real time Market News: https://twitter.com/FNMgroup

Follow us on Linkedin: https://www.linkedin.com/in/financialnewsmedia/

 

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM was compensated forty nine hundred dollars for news coverage of the current press releases issued by Avant Technologies, Inc. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

 

SOURCE: FN Media Group

Las Vegas, NV – August 14, 2024 – Avant Technologies, Inc. (OTCQB:AVAI) (“Avant”), an emerging technology company developing solutions in artificial intelligence (AI) infrastructure while exploring additional technologies in the biotechnology and healthcare sectors, today announced a significant initiative to improve patient care by creating an advanced AI-powered healthcare infrastructure. This new platform will utilize machine learning and advanced computing to empower healthcare providers and patients, which will enhance care delivery and monitoring. Healthcare-focused applications, such as “intelligent agents,” will directly benefit from this platform, which includes built-in features specifically designed for healthcare applications for professionals and patients.

 

Avant’s vision for the future of healthcare revolves around integrating with existing systems and providing a suite of built-in infrastructure and intelligent features. These features include first-line advising agents that offer personalized guidance to patients, advanced analytics to uncover hidden patterns and optimize treatment plans, and tailored treatment protocols based on individual patient data. The platform will also include a predictive health analysis feature for early intervention and medication management tools to ensure optimal adherence and effectiveness.

 

One of the infrastructure’s key focuses is a highly secure connection to clinic and hospital patient databases. This ensures privacy and compliance while enabling remote telemedicine features. It also expands access to quality healthcare, especially in underserved areas.

 

“Our mission is to utilize the latest advancements in AI, including the massive potential of future quantum computing, to create a healthcare ecosystem where healthcare applications can naturally incorporate smart features for patient care, ensuring that every patient receives the best possible care,” said Kenneth L. Waggoner, Chief Executive Officer at Avant Technologies. “We believe that evidence-based medicine and intelligent resource allocation will pave the way for a healthier future for all.”

 

Avant’s ambition extends beyond improving patient outcomes. By optimizing healthcare spending through intelligent data-driven insights, the company aims to make quality healthcare more accessible and affordable for everyone. This initiative reinforces Avant’s commitment to utilizing cutting-edge technology to create a more efficient, effective, and equitable healthcare system for the future.

 

About Avant Technologies, Inc.

Avant Technologies, Inc. is at the forefront of AI innovation, specializing in the development and deployment of advanced data processing solutions. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

More information about Avant can be found at https://avanttechnologies.com

 

You can also follow us on social media at:

https://www.linkedin.com/company/avant-technologies-ai

https://www.facebook.com/AvantTechAI

https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

CONTACT:
Avant Technologies, Inc.
info@avanttechnologies.com

 

SOURCE: Avant Technologies, Inc.

Las Vegas, NV – June 5, 2024 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), a leader in artificial intelligence (AI) technology company specializing in cutting edge AI and data center infrastructure solutions, today announced it has entered into a Binding Letter of Intent (“BLOI”) with Florida-based Flow Wave, LLC (“FW”), a pioneer in immersible computer server development.  This agreement paves the way for Avant to acquire up to 50 state-of-the-art high-performance immersible computer servers from FW in a deal valued at $50 million.

 

This transaction, subject to a mutually satisfactory definitive agreement (“Definitive Agreement”), signifies a major leap forward for Avant as it expects to lead the way in providing distributed submerged infrastructure solutions.  With a commitment to innovation and sustainability, this acquisition of up to 50 high-performance immersible computer servers allows Avant to address the complex challenges of the digital era with cutting-edge solutions.

 

Flow Wave’s Immersion-as-a-Service computer servers utilize state-of-the-art immersion cooling technologies, which significantly enhances compute performance and energy efficiency.  Flow Wave’s innovative approach addresses the growing demands for higher processing power and sustainability in the data center industry.  The partnership with Flow Wave aligns perfectly with Avant’s commitment to enabling top-tier AI infrastructure solutions and optimizing operational efficiencies.

 

Key Features of Flow Wave Immersible AI Supercomputer Servers:

 

• Unparalleled Compute Performance: Designed to handle intensive AI and machine learning workloads. These servers offer superior processing power, which allow for faster and more efficient data analysis.

 

• Power Consumption Efficiencies: Immersion cooling technology reduces the energy consumption required for cooling, leading to substantial cost savings and a smaller carbon footprint.

 

• Compact Physical Design: Immersible servers are compact and sleek, making them ideal for AI data centers with limited floor space or those seeking to optimize their existing infrastructure. The compact design also reduces the overall weight and size of the server, making it easier to transport and install.

 

• Enhanced Reliability: The immersible design improves hardware longevity and reliability, reducing downtime and maintenance costs.

 

“Avant’s revolutionary AI software platform is poised to transform the landscape of data center management,” said William Hisey, Avant’s Chief Executive Officer.  “By integrating proprietary machine learning algorithms with open-source innovations into those servers, Avant is developing a highly intelligent system designed to optimize resource allocation, enhance performance, and drive unprecedented levels of efficiency and automation.  This marks the beginning of a new era for Avant Technologies, positioning us at the forefront of the supercomputer-driven data center industry and setting new standards for managing and storing AI applications.”

 

The Company expects to announce additional details regarding the proposed acquisition when a definitive agreement is executed.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is at the forefront of AI innovation, specializing in the development and deployment of advanced data processing solutions. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant Technologies serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 

About Flow Wave, LLC

 

Flow Wave, LLC, through its innovative Immersion-as-a-Service offering, is a leading developer of next-generation server technologies, dedicated to enhancing the performance and sustainability of data centers worldwide.  By leveraging immersion cooling and other innovative approaches, Flow Wave aims to revolutionize the way data centers operate, offering solutions that meet the growing demands for computational power and environmental responsibility.

 

More information about Avant Technologies can be found at https://avanttechnologies.com

You can also follow us on social media at:

 

https://twitter.com/AvantTechAI

https://www.linkedin.com/company/avant-technologies-ai

https://www.facebook.com/AvantTechAI

https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.”  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:

Avant Technologies, Inc.

info@avanttechnologies.com

 

Source:  Avant Technologies, Inc.

Las Vegas, NV –  May 23, 2024 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), a leading innovator and enabler of AI infrastructure technology, announces its engagement with Wired4Tech, a renowned AI infrastructure consulting firm.

 

As part of its existing technology services agreement with Wired4Tech, Avant Technologies has engaged Wired4Tech to conduct comprehensive performance benchmarking of a next-generation AI cloud server that Avant is evaluating for future use in its AI data center cloud infrastructure.

 

Wired4Tech’s performance benchmarking will encompass a range of crucial metrics, including response time, throughput, CPU and memory usage, disk I/O, network latency, and error rates. These metrics are essential for assessing the server’s ability to handle complex AI workloads efficiently and reliably.  Additionally, Wired4Tech will measure the server’s power consumption and anticipated cost savings.

 

Response time will be evaluated to measure the speed at which the server responds to various actions, providing insight into its overall responsiveness. Throughput analysis will assess the server’s data transfer capabilities, considering factors such as file size, cached or uncached content, and available network bandwidth.

 

Furthermore, CPU and memory usage will be closely monitored to gauge the server’s processing power and memory management efficiency. Disk I/O performance will be evaluated to ensure smooth data access and storage operations, while network latency measurements will provide valuable information on the server’s communication speed with external systems.

 

“We are excited to engage Wired4Tech to benchmark the performance of an innovative, next-generation AI server,” said William Hisey, Chief Executive Officer, at Avant Technologies. “By conducting rigorous benchmark testing of this promising server technology, we expect to validate its expected performance and cost-saving benefits.”

 

The results of the benchmark testing will enable Avant Technologies to further execute on its AI infrastructure business strategy.

 

About Avant Technologies, Inc.

 

Avant Technologies leads the way in providing distributed submerged infrastructure solutions. With a commitment to innovation and sustainability, Avant Technologies addresses the complex challenges of the digital era with cutting-edge solutions.

 

More information about Avant Technologies can be found at https://avanttechnologies.com

You can follow us on social media at:

 

https://www.linkedin.com/company/avant-technologies-ai
https://www.youtube.com/@AvantTechAI
https://twitter.com/AvantTechAI
https://www.facebook.com/AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

Source:  Avant Technologies, Inc.

Las Vegas, NV – April 9, 2024 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an artificial intelligence technology (AI) company specializing in developing innovative and advanced AI and AI infrastructure solutions, today announces the completion of its acquisition of privately held healthcare technology and data integration services firm, Wired-4-Health.

 

Unified by a shared objective to propel the healthcare data interoperability landscape forward, this strategic merger leverages cutting-edge AI and amplified computational capabilities. This potent combination empowers healthcare and life sciences organizations to navigate the complexities of data and system interoperability with unprecedented efficiency. By streamlining transaction processing, health outcomes analytics, and compliance adherence, this union fosters enhanced performance, improved data integrity, and a more cost-effective, scalable infrastructure for customers.

 

“Our strategy behind this acquisition was to enable Avant to deliver best-in-class data and system interoperability support services to the healthcare and life sciences sectors powered by AvantAI® and our high-density compute capabilities,” said Tim Lantz, Chief Executive Officer of Avant Technologies. “At the same time, this exciting combination significantly strengthens our financial profile, offers massive commercial growth opportunities in one of Avant’s largest target markets, and bolsters our internal customer support and R&D capabilities.”

 

The healthcare sector currently grapples with a confluence of intensifying pressures. Providers face an unrelenting demand to elevate patient outcomes while simultaneously reducing costs. This exigency coincides with an unprecedented prevalence of chronic illness and clinician burnout. Despite the transformative potential of digitalization within healthcare, a crucial impediment persists. The lack of standardized data protocols renders the vast troves of information generated by this digital revolution immensely intricate and expensive to utilize. Consequently, the potential for data-driven solutions to the industry’s most pressing challenges remains unrealized.

 

“In the near term, if the healthcare industry expects to succeed in lowering costs while improving quality, the deployment of advanced AI, combined with more powerful, cost-effective compute capabilities will be critical to that success,” said Angela Harris, Avant’s Chief Operating Officer. “The addition of Wired-4-Health will position Avant as a key contributor in helping healthcare organizations solve complex problems at the intersection of cost, quality, compliance and technology.”

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an artificial intelligence technology company specializing in creating and developing innovative and advanced AI infrastructure solutions designed to revolutionize the landscape for AI software development companies and other companies that require immense, scalable computing power, such as scientific simulations, climate modeling, protein folding analysis, and big data processing. The Company also employs its highly sophisticated machine and deep learning AI system, Avant! AI, to support a more efficient and secure operating environment.

 

More information about Avant Technologies can be found at https://avanttechnologies.com

You can follow us on social media at:

https://www.linkedin.com/company/avant-technologies-ai

https://www.youtube.com/@AvantTechAI

https://www.facebook.com/AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:

Avant Technologies, Inc.

info@avanttechnologies.com

 

Source:   Avant Technologies, Inc.

Las Vegas, NV –  March 20, 2024 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an artificial intelligence technology (AI) company specializing in developing innovative and advanced AI and AI infrastructure solutions, today announced that it has entered into negotiations to acquire a privately held healthcare technology and data integration services firm in a cash-and-stock transaction valued at approximately $2 million.

 

Financial and Strategic Benefits of this Acquisition for Avant:

 

• This potential acquisition would significantly improve Avant’s financial health due to the immediate gains in revenue and operating cash flow generated from the existing long-term customer contracts Avant would inherit.
• Strengthens Avant’s expertise and reputation in handling healthcare, clinical, and financial data. This will boost the Company’s sales and execution capabilities within the healthcare sector, which has become a booming market for AI research, development, and adoption.
• Creates a well-established and experienced professional services team within Avant, which allows the company to effectively address the increasing needs of both existing and potential customers.
• Unlocks profitable new opportunities to sell additional services (upselling) and related products (cross-selling) to our existing customer base. This includes expanded professional services, automated data integration, powered by AvantAI®, and enhanced infrastructure through our new high-density compute offerings.
• This potential acquisition bolsters Avant’s internal software development team, which accelerates the delivery of Avant’s new high-density computing solutions, and supports the Company’s ongoing research and development efforts.

 

“We are excited about this opportunity to accelerate Avant’s growth within the healthcare sector and create new value for our customers and shareholders,” said Timothy Lantz, Avant’s Chief Executive Officer. “This acquisition will serve to further strengthen our financial position, unlock new growth opportunities in one of the top segments of AI adoption, and bolster our internal product development and client services capabilities.”

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an artificial intelligence technology company specializing in creating and developing innovative and advanced AI infrastructure solutions designed to revolutionize the landscape for AI software development companies and other companies that require immense, scalable computing power, such as scientific simulations, climate modeling, protein folding analysis, and big data processing. The Company also employs its highly sophisticated machine and deep learning AI system, Avant! AI™, to support a more efficient and secure operating environment.

 

More information about Avant Technologies can be found at https://avanttechnologies.com

 

You can follow us on social media at:
https://www.linkedin.com/company/avant-technologies-ai
https://www.youtube.com/@AvantTechAI
Tweets by AvantTechAI
https://www.facebook.com/AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

SOURCE:  Avant Technologies, Inc.

Las Vegas, NV – March 4, 2024 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an artificial intelligence technology (AI) company specializing in creating and developing innovative and advanced AI infrastructure solutions, announced today that Avant is experiencing growing demand for its planned high-density compute infrastructure and distributed supercomputing solutions.

 

In September 2023, Avant announced plans to begin working on the design and production of a faster, more powerful, and more cost-effective compute infrastructure aimed at supporting AI, machine learning and other big data use cases. Last month Avant announced its partnership with the Florida-based technology development firm Wired4Tech to help support “last mile” development and testing of Avant’s new high-density private cloud infrastructure solution. On the heels of that recent announcement, the company shared today that it is seeing strong prelaunch momentum for its new high-density compute solution, which is expected to be available later this year.

 

Avant’s VP of Business Development, Jared Pelski, stated, “The team has been working hard on bringing new technology to market that will address critical issues and growing opportunities in the current data center infrastructure landscape. We’re starting to see that effort and innovation play out on the demand side as we continue to ramp up our pre-launch selling activities. Our qualified pipeline has almost doubled since December and new lead volume for February was up over 500%, month-over-month.”

 

The global cloud computing market size was valued at $545.8 billion in 2022, and it is projected to reach $1.24 trillion by 2027(1). Within that broader landscape, private cloud and AI are two of the fastest growing subsegments with rapidly increasing demand for better, more cost-effective, and scalable solutions. These early indicators of demand for Avant’s new high-density compute infrastructure are consistent with commercial growth numbers that have been reported from traditional data centers. A Q3 2023 report by TD Cowen, entitled, “A Tsunami of AI Demand Hits the Data Center Market,” highlighted annualized growth rates in the third-party data center market of more than 80%, and went on to cite a specific example of a large data center whose sales pipeline doubled in size over a 90-day period(2).

 

“We’ve made great progress over the past several months and are encouraged by the growing enthusiasm we’re seeing from the market, but we still have a lot of hard work ahead of us,” said Timothy Lantz, Chief Executive Officer of Avant. “The fact that early interest in our next generation infrastructure is coming from multiple customer segments, including data centers, universities, healthcare, government, construction, and tech is a great indicator of how extensively AI and big data are being woven into the fabric of our economy and our everyday lives. The magnitude of reach and positive impact Avant can make in this space is a huge motivator to our team and inspires us to give our best every day.”

 

1. Source: Cloud Computing Market; Markets and Markets; November 2022
2. Source: A Tsunami of AI Demand Hits the Data Center Market; July 2023

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an artificial intelligence technology company specializing in creating and developing innovative and advanced AI infrastructure solutions designed to revolutionize the landscape for AI software development companies and other companies that require immense, scalable computing power, such as scientific simulations, climate modeling, protein folding analysis, and big data processing. The Company also employs its highly sophisticated machine and deep learning AI system, Avant! AI™, to support a more efficient and secure operating environment.

 

More information about Avant Technologies can be found at https://avanttechnologies.com
You can follow us on social media at:
https://www.linkedin.com/company/avant-technologies-ai
https://www.youtube.com/@AvantTechAI
Tweets by AvantTechAI
https://www.facebook.com/AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

 

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

 

SOURCE:  Avant Technologies, Inc.

Vancouver, Kelowna and Delta, BC – February 22, 2024 – Investorideas.com, a global news source and expert investing resource covering AI stocks issues a snapshot for the sector featuring Avant Technologies, Inc. (OTCQB: AVAI), an artificial intelligence (AI) technology company specializing in creating and developing innovative and advanced AI infrastructure solutions.

 

Read the full article on Investorideas.com
https://www.investorideas.com/News/2024/technology/02220AI-Stocks.asp

 

With AI stocks showing impressive gains in 2023, there are high expectations for 2024 as the technology advances exponentially and investment continues to pour into the sector.

 

According to a report this week from Barron’s, “Microsoft is on an artificial-intelligence charm offensive around the world. The technology company’s latest commitment is for around $5.6 billion in AI investment across Europe.”

 

With the tech giants all battling for leadership, investors are looking for smaller companies with niche market opportunities, to find the next potential big thing in AI.

 

Focusing on security applications for AI, Avant Technologies, Inc. (OTCQB: AVAI) just announced that it will be expanding its scope for planned enhancements to Avant! AI™ with the intent to deliver best in class security in conjunction with its high-performance data center infrastructure. As one of the earliest companies to market with a functional generative AI, Avant’s announcement marks a significant advancement in data center information management, compliance and cybersecurity.

 

From the news: Avant! AI™ seamlessly integrates with industry-standard data science tools and algorithms, enabling organizations to harness the power of data for deeper insights and informed decision-making. Planned advancements in Avant’s proprietary gen AI will have the dual aim of providing early detection of potential security vulnerabilities and recommendations for proactive interventions to enhance cybersecurity baselines, mitigate risks and ensure compliance in today’s dynamic digital landscape.

 

“As a former CISO, I am extremely excited about adding AI-enhanced cybersecurity to our customer-facing toolkit,” said Danny Rittman, CISO at Avant Technologies. “Cybersecurity and compliance are more important than ever, and we are passionate about supporting our customers and partners to stay ahead of the curve – both now and in the future.”

 

From the news: On the cybersecurity front, Avant will serve as a vigilant guardian – supervising all cybersecurity aspects within the data center environment. From continuous monitoring and vulnerability assessment to proactive risk assessments and real-time response in case of cyber-attack incidents, Avant intends to empower its customers to achieve and maintain a robust cybersecurity posture and threat mitigation capabilities – going beyond standard cybersecurity to maintain data compliance, privacy compliance, and necessary standard compliances according to specific application types. By automating compliance management processes, organizations can achieve regulatory compliance while reducing administrative burden and mitigating compliance-related risks.

Avant CEO, Timothy Lantz said, “The rapid advancements in AI are unlocking tremendous opportunities and potential across almost every facet of our lives, but those same advancements can also pose an increased threat when used by those with an intent to harm. In today’s digital world cybersecurity is of paramount importance and Avant is committed to providing our customers with the necessary tools to ensure the safety and security of their information and that of their end-users.”

 

Avant! AI™ represents a paradigm shift in data center management, offering organizations a strategic advantage in optimizing performance, enhancing cybersecurity, and ensuring compliance in their IT infrastructure.

 

According to a recent article looking at how one AI stock, C3.ai performed last year, “The stock gained 157% in 2023, far outpacing the S&P 500’s 24% rise.”

 

C3.ai will host its fifth annual AI conference, C3 Transform 2024, from March 5-7, 2024 in Boca Raton, Florida. This event brings together business leaders, technical experts, thought leaders, and C3 AI customers to discuss enterprise AI innovation, performance and value; this year, the focus is on how generative AI is delivering enormous productivity and efficiency benefits across industries.

 

From the news: “At its core, C3 Transform is where the vision of enterprise AI comes to life,” said C3 AI CEO and Chairman, Thomas M. Siebel. “Generative AI is changing the future of business, and leaders across every sector are turning to it to improve efficiency, productivity, and workforce skills and knowledge. By bringing together experts from C3 AI and early adopters who can speak to the value of enterprise AI, C3 Transform gives attendees the chance to discover exactly how they can use generative AI securely and effectively.”

 

A recent Form 13F SEC filing for Nvidia grabbed investor attention showing investment in SoundHound AI (NASDAQ: SOUN), a voice AI solutions company. Investors will be able to see if the company performance matches expectations, as they announced that it will report its 2023 fourth quarter and full year financial results on Thursday, February 29, 2024 after market close. The company will host a conference call and webcast to review the results on the same day.

 

Keyvan Mohajer, Co-Founder and CEO, and Nitesh Sharan, CFO will host the conference call at 2:00 p.m. PT / 5:00 p.m. ET. A live audio webcast will be available at investors.soundhound.com and a replay will be available at the same location.

 

Knightscope, Inc. (NASDAQ: KSCP), an innovator in robotics and artificial intelligence technologies focused on public safety, recently announced that it deployed two more of its K5 Autonomous Security Robots (“ASRs”) driven by its proprietary AI software to enhance safety measures at a Washington casino and at a security services company that recently became a reseller in the Knightscope Authorized Partner (“KAP”) program.

 

The K5 ASR is the Company’s fully autonomous (i.e., no human intervention needed to operate) outdoor robot capable of watching over a property 24/7/365. The robot’s commanding size, along with its conspicuous lighting, strobe lights, broadcast messages and patrol sounds effectively deter illicit activities, while its sensors gather evidentiary-quality video and publicly available data to aid investigations. The robots also provide a unique guest experience with branded graphics, a client-chosen voice for custom audio broadcast messaging, and improved access to emergency services.

 

As all investors turned to Nvidia’s Q4 earnings this week for insight into the direction of the sector, it is apparent that the AI game in still in its infancy. It is growing at a pace beyond any predictions. OpenAI’s ChatGPT surpassed 1 million users in 5 days and according to the latest available data (December), ChatGPT currently has around 180.5 million users.

 

Research more AI stocks with Investorideas.com free stock directory
https://www.investorideas.com/TSS/Stock_List.asp#Robotics

 

About Investorideas.com – Big Investing Ideas

 

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure: This article featuring Avant Technologies, Inc. is part of Investorideas.com paid for article content creation. Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

 

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp

 

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on Twitter @investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas

Contact Investorideas.
800 665 0411

 

SOURCE:  Investorideas.com

Las Vegas, NV – February 21, 2024 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an artificial intelligence technology (AI) company specializing in creating and developing innovative and advanced AI infrastructure solutions, announced today that it will be expanding its scope for planned enhancements to Avant! AI™ with the intent to deliver best in class security in conjunction with its high-performance data center infrastructure.  As one of the earliest companies to market with a functional generative AI, Avant’s announcement marks a significant advancement in data center information management, compliance, and cybersecurity.

 

Avant! AI™ seamlessly integrates with industry-standard data science tools and algorithms, enabling organizations to harness the power of data for deeper insights and informed decision-making. Planned advancements in Avant’s proprietary gen AI will have the dual aim of providing early detection of potential security vulnerabilities and recommendations for proactive interventions to enhance cybersecurity baselines, mitigate risks and ensure compliance in today’s dynamic digital landscape.

 

“As a CIO and former CISO, I am extremely excited about adding AI-enhanced cybersecurity to our customer-facing toolkit,” said Danny Rittman, CIO at Avant Technologies. “Cybersecurity and compliance are more important than ever, and we are passionate about supporting our customers and partners to stay ahead of the curve – both now and in the future.”

 

On the cybersecurity front, Avant will serve as a vigilant guardian – supervising all cybersecurity aspects within the data center environment. From continuous monitoring and vulnerability assessment to proactive risk assessments and real-time response in case of cyber-attack incidents, Avant intends to empower its customers to achieve and maintain a robust cybersecurity posture and threat mitigation capabilities – going beyond standard cybersecurity to maintain data compliance, privacy compliance, and necessary standard compliances according to specific application types. By automating compliance management processes, organizations can achieve regulatory compliance while reducing administrative burden and mitigating compliance-related risks.

 

Avant CEO, Timothy Lantz, said, “The rapid advancements in AI are unlocking tremendous opportunities and potential across almost every facet of our lives, but those same advancements can also pose an increased threat when used by those with an intent to harm.  In today’s digital world cybersecurity is of paramount importance and Avant is committed to providing our customers with the necessary tools to ensure the safety and security of their information and that of their end-users.”

 

Avant! AI™ represents a paradigm shift in data center management, offering organizations a strategic advantage in optimizing performance, enhancing cybersecurity, and ensuring compliance in their IT infrastructure.

 

About Avant Technologies, Inc.

 

Avant Technologies, Inc. is an artificial intelligence technology company specializing in creating and developing innovative and advanced AI infrastructure solutions designed to revolutionize the landscape for AI software development companies and other companies that require immense, scalable computing power, such as scientific simulations, climate modeling, protein folding analysis, and big data processing.  The Company also employs its highly sophisticated machine and deep learning AI system, Avant! AI™, to function as both a versatile and customizable AI solution in a host of industries and applications.

 

More information about Avant Technologies can be found at https://avanttechnologies.com

 

You can also follow us on social media at:

https://twitter.com/AvantTechAI

https://www.linkedin.com/company/avant-technologies-ai

https://www.facebook.com/AvantTechAI

https://www.youtube.com/@AvantTechAI

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements”.  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.

 

Contact:

SOURCE:  Avant Technologies, Inc.

info@avanttechnologies.com

Las Vegas, NV – February 12, 2024 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an artificial intelligence technology (AI) company specializing in creating and developing innovative and advanced AI infrastructure solutions, announced today that it plans to begin additional training on AvantAI™ to enhance its latest developments in high-performance data center infrastructure. As one of the earliest companies to bring a gen AI to market, Avant’s announcement marks a significant advancement in data center operations management.

 

“We are thrilled to introduce our groundbreaking AI technology for intelligent data center management,” said Danny Rittman, CISO at Avant Technologies, Inc. “With our innovative solution, organizations can unlock new levels of performance and efficiency in their data center operations, driving business success in today’s digital era.”

 

By leveraging AvantAI™ to enhance monitoring capabilities, organizations will be able to gain real-time insights into their data center infrastructure, thereby enabling proactive management of maintenance, uptime, and overall performance. By analyzing vast amounts of data, the AI system will be able to forecast potential problems before they happen and provide proactive solutions to avoid outages or malfunctions, ensuring uninterrupted operation of critical systems. In addition to data monitoring and predictive analysis, AvantAI™ will help oversee and monitor all aspects of data traffic efficiency – offering enhanced capabilities to dynamically adjust resource allocation and routing, maximize performance and minimize latency, and achieve throughput and responsiveness in their data center environments.

Avant CEO Timothy Lantz commented, “By leveraging Avant’s legacy AI technology in combination with our newest innovations in high-density computing infrastructure, we are aspiring to create a true paradigm shift in data center management – offering our customers and partners an unparalleled advantage in performance and cost optimization.”

About Avant Technologies, Inc.

Avant Technologies, Inc. is an artificial intelligence technology company specializing in creating and developing innovative and advanced AI infrastructure solutions designed to revolutionize the landscape for AI software development companies and other companies that require immense, scalable computing power, such as scientific simulations, climate modeling, protein folding analysis, and big data processing. The Company also employs its highly sophisticated machine and deep learning AI system, AvantAI™, to function as both a versatile and customizable AI solution in a host of industries and applications.

More information about Avant Technologies can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.”  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

Contact:
Avant Technologies, Inc.
info@avanttechnologies.com

Source:  Avant Technologies, Inc